# Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

> **NCT04992858** · PHASE2 · WITHDRAWN · sponsor: **Sunshine Lake Pharma Co., Ltd.**

## Conditions studied

- Advanced NSCLC

## Interventions

- **DRUG:** CT053PTSA

## Key facts

- **NCT ID:** NCT04992858
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-27
- **Primary completion:** 2024-09-09
- **Final completion:** 2024-12-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn proactively due to the company's development strategy adjustment and changes in the drug R\&D direction.
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04992858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04992858, "Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04992858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*